INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
18/01/2020
Voltar para busca
Dado oficial do USPTO
PATRYS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
60
Atualização mais recente
18/01/2020
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
12/06/2007
Data de registro
28/04/2009
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
25/04/2019
Última transação
25/04/2019
Escritório responsável
United States Patent and Trademark Office
Código da situação
706
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
11
Localização do titular
South Melbourne, AU
Examinador
STEPHENS,SONYA B
Unidade examinadora
L90
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
PATRYS LIMITED
PATRYS LIMITED
Patrys Pty Ltd
Representantes
Mainak H. Mehta Procopio, Cory, Hargreaves & Savitch LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and biotechnological preparations and substances for human medicinal purposesfor the treatment of cancers and autoimmune diseases; veterinary preparations and substances for animal medicinal purposesfor the treatment of cancers and autoimmune diseases; diagnostic preparations for medical use and reagents for medical usefor diagnosis of human diseasessuch as cancer and autoimmune diseases; pharmaceutical and biotechnological preparationsantibodies for the treatment of cancers and autoimmune diseases; pharmaceutical and biotechnological preparationsantibody fragments and antibody conjugates for the treatment of cancers and autoimmune diseases; pharmaceutical and biotechnological preparations for the reconstruction and repair of antibodies for use in the field of cancers and autoimmune diseases; monoclonal antibodies for medical and veterinary usereagents for the diagnosis and prognosis of human and animal diseasessuch as cancer and autoimmune diseases; proteins for medical usefor detecting antibodies; clinical medical reagentsreagents for use in the development of monoclonal antibodies; proteins for medical usefor binding antibodies; reagents for veterinary usereagents for the development of monoclonal antibodies; vaccines; vaccines against cancerviral infection and bacterial infectionvaccines for human use; vaccine adjuvants; medical and veterinary diagnostic reagentsreagents for use in tests for the diagnosis and prognosis of human and animal diseasessuch as cancer and autoimmune diseases; reagents for research purposesdiagnostic reagents for medical research applications; cells for medical or clinical userecombinant human protein production cell lines; proteins for medical use in the field of recombinant DNA technology; biological reagents for medical purposes in the field of molecular biology
Classe 42
Scientific research and developmentclinical research and scientific advisory and consultancy services all in relation to antibody production; drug discovery; research and development of vaccinesvaccine screening; scientific research advisory services relating to diagnostic products for diagnosing cancers and autoimmune diseases; diagnostic testing servicesproviding reagent sample testing and diagnostic services for others in the field of science; medical research services; scientific research for medical purposes; pharmaceutical research services; scientific research advisory services comprising the preparation of reports relating to the performance and analysis of research and the outcomes of research in the field of pharmaceuticals and biotechnology; biochemicalchemicalmicroscopyspectroscopyphysiologicalhistologicalelectrical analysis of biological tissues for medical research; scientific research and development services for the production of antibodies; scientific research and development services for the discovery and development of proteins that bind to antibodies
Publicações
Histórico de despachos e eventos da marca no USPTO.
60 publicações encontradas
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
25/12/2019
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
25/04/2019
71AG
REGISTERED-SEC.71 ACCEPTED
25/04/2019
ES71
TEAS SECTION 71 RECEIVED
09/04/2019
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
28/04/2018
RNWL
INTERNATIONAL REGISTRATION RENEWED
29/06/2017
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/07/2016
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
11/09/2015
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
19/08/2015
INPC
INVALIDATION PROCESSED
19/08/2015
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
06/07/2015
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
06/11/2014
71AG
REGISTERED-SEC.71 ACCEPTED
06/11/2014
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/10/2014
ES71
TEAS SECTION 71 RECEIVED
22/09/2014
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/04/2014
NREP
NEW REPRESENTATIVE AT IB RECEIVED
29/11/2013
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/01/2013
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
11/11/2011
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/08/2009
FIMP
FINAL DISPOSITION PROCESSED
10/08/2009
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
28/07/2009
R.PR
REGISTERED-PRINCIPAL REGISTER
28/04/2009
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
06/04/2009
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
13/03/2009
PUBO
PUBLISHED FOR OPPOSITION
10/02/2009
NPUB
NOTICE OF PUBLICATION
21/01/2009
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
08/01/2009
EXPT
EXPARTE APPEAL TERMINATED
27/12/2008
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
19/12/2008
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/12/2008
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/12/2008
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
16/12/2008
EXPI
EX PARTE APPEAL-INSTITUTED
16/12/2008
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
16/12/2008
EXAF
EXPARTE APPEAL RECEIVED AT TTAB
16/12/2008
CHLD
CHANGE OF OWNER RECEIVED FROM IB
05/12/2008
GNS1
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
31/10/2008
GNCF
CONTINUATION OF FINAL REFUSAL E-MAILED
31/10/2008
CNCF
ACTION CONTINUING A FINAL - COMPLETED
31/10/2008
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/09/2008
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/09/2008
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
15/09/2008
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
15/09/2008
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
15/09/2008
CNFR
FINAL REFUSAL MAILED
23/06/2008
CNFR
FINAL REFUSAL WRITTEN
21/06/2008
ACEC
AMENDMENT FROM APPLICANT ENTERED
06/05/2008
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/05/2008
ALIE
ASSIGNED TO LIE
01/05/2008
PAPER RECEIVED
29/04/2008
RFNT
REFUSAL PROCESSED BY IB
08/02/2008
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
16/01/2008
RFRR
REFUSAL PROCESSED BY MPU
16/01/2008
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
16/01/2008
CNRT
NON-FINAL ACTION WRITTEN
15/01/2008
DOCK
ASSIGNED TO EXAMINER
21/12/2007
NWAP
NEW APPLICATION ENTERED
21/12/2007
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
20/12/2007
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PATRYS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.